5-[8-morpholin-4-yl-2-(2-quinolin-2-ylethenyl)imidazo[1,2-a]pyrazin-5-yl]-1,1-dioxo-1,2-benzothiazol-3-one
C28H22N6O4S — CID 154071238
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-[8-morpholin-4-yl-2-(2-quinolin-2-ylethenyl)imidazo[1,2-a]pyrazin-5-yl]-1,1-dioxo-1,2-benzothiazol-3-one
5-[8-morpholin-4-yl-2-(2-quinolin-2-ylethenyl)imidazo[1,2-a]pyrazin-5-yl]-1,1-dioxo-1,2-benzothiazol-3-one (PubChem CID 154071238) has the molecular formula C28H22N6O4S and a molecular weight of 538.59 g/mol. Its IUPAC name is 5-[8-morpholin-4-yl-2-(2-quinolin-2-ylethenyl)imidazo[1,2-a]pyrazin-5-yl]-1,1-dioxo-1,2-benzothiazol-3-one.
Molecular Properties
| Compound Name | 5-[8-morpholin-4-yl-2-(2-quinolin-2-ylethenyl)imidazo[1,2-a]pyrazin-5-yl]-1,1-dioxo-1,2-benzothiazol-3-one |
|---|---|
| PubChem CID | 154071238 |
| Molecular Formula | C28H22N6O4S |
| Molecular Weight | 538.59 g/mol |
| Exact Mass | 538.14 |
| IUPAC Name | 5-[8-morpholin-4-yl-2-(2-quinolin-2-ylethenyl)imidazo[1,2-a]pyrazin-5-yl]-1,1-dioxo-1,2-benzothiazol-3-one |
| SMILES | O=C1NS(=O)(=O)c2ccc(-c3cnc(N4CCOCC4)c4nc(C=Cc5ccc6ccccc6n5)cn34)cc21 |
| InChI | InChI=1S/C28H22N6O4S/c35-28-22-15-19(6-10-25(22)39(36,37)32-28)24-16-29-26(33-11-13-38-14-12-33)27-31-21(17-34(24)27)9-8-20-7-5-18-3-1-2-4-23(18)30-20/h1-10,15-17H,11-14H2,(H,32,35) |
| InChIKey | XDSLADWQLISOLJ-UHFFFAOYSA-N |
| XLogP | 3.38 |
| TPSA | 118.79 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 39 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 538.59 |
| LogP ≤ 5 | 3.38 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 154071238 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.